Disialoganglioside GD2 and Disialoganglioside GD3 (GD2 and GD3)

GD2 and GD3 are disialogangliosides, a class of sialic acid-containing glycosphingolipids located on the outer leaflet of the plasma membrane [1]. They play significant roles in cell-cell recognition, adhesion, and signal transduction, particularly during the development of the central and peripheral nervous systems [2]. In healthy adults, their expression is highly restricted to the brain, peripheral nerves, and melanocytes, but they are significantly overexpressed in various tumors of neuroectodermal and mesenchymal origin, such as neuroblastoma, melanoma, and osteosarcoma [1, 3]. This differential expression pattern makes them valuable targets for cancer immunotherapy [3]. Therapeutic interventions targeting these gangliosides include monoclonal antibodies like dinutuximab and naxitamab, which have become standard treatments for high-risk neuroblastoma [4, 5]. These agents work by inducing antibody-dependent cellular cytotoxicity and complement-mediated lysis of tumor cells [4]. Despite their efficacy, targeting GD2 is associated with significant clinical challenges, most notably intense neuropathic pain caused by antibody binding to GD2 on peripheral nerve fibers [5, 6]. Ongoing research continues to explore GD2 and GD3 as targets for next-generation therapies, including CAR-T cells and cancer vaccines, to improve outcomes in solid tumors.

Other names

GD2 gangliosideGD3 gangliosideDisialoganglioside G2Disialoganglioside G3Neu5Ac(alpha2-8)Neu5Ac(alpha2-3)Gal(beta1-4)Glc(beta1-1)CerGalNAc(beta1-4)[Neu5Ac(alpha2-8)Neu5Ac(alpha2-3)]Gal(beta1-4)Glc(beta1-1)Cer

Monoclonal antibodies targeting GD2 and GD3 gangliosides primarily act through immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [4, 5]. These processes involve the recruitment of natural killer cells, macrophages, and the complement system to induce lysis of the target tumor cells. Additionally, binding to these gangliosides can directly trigger apoptosis or interfere with cell signaling pathways and adhesion molecules, such as integrins and focal adhesion kinase (FAK), which are essential for tumor cell survival, migration, and metastasis [2, 3].